Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 23;221(1):e202103074. doi: 10.1083/jcb.202103074

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Yu-Kemp et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 8. — Blebbistatin (myosin ATPase inhibitor) treatment disrupted assembly of myosin stacks and altered F-actin structures at the ZA. (A–H) Representative images of different time points during recovery. Control vs. blebbistatin (blebb). At middle time points, assembly of expansive stacks of myosin is lost (C′ vs. D′, arrows), and later in recovery, the tight sarcomeric ZA array of myosin is lost (E′ vs. F′; G′ vs. H′). Actin bundling at the ZA is disrupted, and instead actin has a spiky appearance (D″, F″, and H″) Also see quantifications in Fig. 7, E–H. (I–K) Formin inhibition does not prevent stimulation by blebbistatin of spiky actin at the ZA (arrows). Boxes indicated areas magnified at right.